Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has shared an update.
IRLAB Therapeutics AB’s interim report for January to September 2025 highlights significant developments, including a successful rights issue that has secured necessary capital for advancing drug candidates IRL1117 and pirepemat. The company also submitted a clinical trial application for a Parkinson’s study to the EMA and received additional funding for the IRL757 study. A new patent for mesdopetam was granted in China, ensuring market exclusivity into the mid-2040s. Financially, the company reported a decrease in net sales and operating profit compared to the previous year, but cash reserves have increased.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK2.50 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a pharmaceutical company focused on developing novel treatments for neurological disorders. The company is engaged in advancing its drug candidates, including IRL1117 and pirepemat, with a particular emphasis on Parkinson’s disease and other central nervous system conditions.
Average Trading Volume: 216,058
Technical Sentiment Signal: Sell
Current Market Cap: SEK209.4M
For detailed information about IRLAB.A stock, go to TipRanks’ Stock Analysis page.